Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2025-06-02T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: CPRX

TL;DR

Catalyst Pharma filed an 8-K on June 1st, details to follow.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on June 2, 2025, reporting an event that occurred on June 1, 2025. The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as key information. No specific financial figures or new material events were detailed in the provided text.

Why It Matters

This filing serves as an official notification to the SEC and investors about significant corporate events or financial updates. The lack of specific details in the provided excerpt means further review of the full filing is needed to understand the implications.

Risk Assessment

Risk Level: low — The filing itself is a routine disclosure and does not inherently present new risks, but the content of the full report may contain material information.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Catalyst Pharmaceuticals, Inc.?

The provided text does not specify the 'Other Events' beyond listing it as an item information category.

What is the significance of the 'Financial Statements and Exhibits' being listed?

This indicates that the filing includes financial information or exhibits, which could be related to recent performance or other corporate actions.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 1, 2025.

What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?

The address is 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134.

What is the SEC file number for Catalyst Pharmaceuticals, Inc.?

The SEC file number is 001-33057.

From the Filing

0001193125-25-133348.txt : 20250602 0001193125-25-133348.hdr.sgml : 20250602 20250602163555 ACCESSION NUMBER: 0001193125-25-133348 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250601 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 251015573 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d17589d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-06-01 2025-06-01     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) 355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On June 1, 2025, Gary Ingenito, MD, PhD, the Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals, Inc. (the “ Company ”) retired from his position. Dr. Ingenito reported to the Company that his decision to retire was not the result of any disagreements between Dr. Ingenito, on the one hand, and the Company, the Compa

View on Read The Filing